[{"address1": "1400 Sierra Point Parkway", "address2": "Building C Suite 200", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "650 822 5500", "fax": "650 636 9773", "website": "https://www.annexonbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barr\u00e9 syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Mr. Douglas  Love Esq., J.D.", "age": 55, "title": "CEO, President & Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 980122, "exercisedValue": 0, "unexercisedValue": 516039}, {"maxAge": 1, "name": "Dr. Dean R. Artis Ph.D.", "age": 62, "title": "Chief Scientific Officer & Executive VP", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 797380, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ted  Yednock Ph.D.", "age": 65, "title": "Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 697760, "exercisedValue": 0, "unexercisedValue": 119297}, {"maxAge": 1, "name": "Ms. Jennifer  Lew", "age": 50, "title": "Executive VP, CFO & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 624195, "exercisedValue": 0, "unexercisedValue": 13124}, {"maxAge": 1, "name": "Mr. Michael  Overdorf M.B.A.", "age": 52, "title": "Executive VP & Chief Business Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 580469, "exercisedValue": 0, "unexercisedValue": 13124}, {"maxAge": 1, "name": "Mr. Henk-Andre  Kroon M.D.", "title": "Senior Vice President of Translational Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jamie  Dananberg M.D.", "age": 65, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.87, "open": 5.77, "dayLow": 5.63, "dayHigh": 6.278, "regularMarketPreviousClose": 5.87, "regularMarketOpen": 5.77, "regularMarketDayLow": 5.63, "regularMarketDayHigh": 6.278, "beta": 1.293, "forwardPE": -5.8, "volume": 1988849, "regularMarketVolume": 1988849, "averageVolume": 2969319, "averageVolume10days": 1847730, "averageDailyVolume10Day": 1847730, "bid": 6.07, "ask": 6.13, "bidSize": 400, "askSize": 200, "marketCap": 641971264, "fiftyTwoWeekLow": 1.57, "fiftyTwoWeekHigh": 8.4, "fiftyDayAverage": 5.2167, "twoHundredDayAverage": 4.413825, "currency": "USD", "enterpriseValue": 328631360, "floatShares": 66977149, "sharesOutstanding": 105414000, "sharesShort": 5157001, "sharesShortPriorMonth": 7278564, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.048899997, "heldPercentInsiders": 0.00387, "heldPercentInstitutions": 0.95888, "shortRatio": 1.01, "shortPercentOfFloat": 0.0586, "impliedSharesOutstanding": 105414000, "bookValue": 2.9, "priceToBook": 2.1, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -120737000, "trailingEps": -1.46, "forwardEps": -1.05, "pegRatio": -0.15, "enterpriseToEbitda": -2.549, "52WeekChange": 0.93949044, "SandP52WeekChange": 0.19608545, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ANNX", "underlyingSymbol": "ANNX", "shortName": "Annexon, Inc.", "longName": "Annexon, Inc.", "firstTradeDateEpochUtc": 1595597400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "39e86d0b-392a-371c-9e14-996bb9ee6158", "messageBoardId": "finmb_279883519", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.09, "targetHighPrice": 30.0, "targetLowPrice": 10.0, "targetMeanPrice": 16.4, "targetMedianPrice": 14.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 264948000, "totalCashPerShare": 2.867, "ebitda": -128903000, "totalDebt": 30785000, "quickRatio": 20.174, "currentRatio": 20.615, "debtToEquity": 11.732, "returnOnAssets": -0.28597, "returnOnEquity": -0.50595003, "freeCashflow": -73527128, "operatingCashflow": -116416000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-25"}]